4-propylethoxybenzene | 101144-94-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-propylethoxybenzene
• 英文别名: 4-propyl-phenetole；4-Aethoxy-1-propyl-benzol；4-Propyl-phenetol；1-ethoxy-4-propyl-benzene；1-Ethoxy-4-propylbenzene
• CAS: 101144-94-9
• 化学式: C₁₁H₁₆O
• 分子量: 164.247
• InChiKey: WPAWAZLEZWMRKD-UHFFFAOYSA-N

物化性质

• 沸点：
  226.5±0.0 °C(Predicted)
• 密度：
  0.916±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-ethoxy-4-(1-propenyl)benzene 在 乙醇 、 sodium 作用下， 生成 4-propylethoxybenzene
  参考文献：
  名称：

  Antifungal Pharmacodynamic Characteristics of Amphotericin B againstTrichosporon asahii, Using Time-Kill Methodology

  摘要：

  AbstractWe determined the MIC of amphotericin B against 45 Trichosporon asahii isolates from various clinical and environmental sources, and used in vitro time‐kill methods to characterize the relationship between amphotericin B concentrations and MIC for four representative T. asahii isolates. Amphotericin B had concentration‐dependent antifungal activity. MICs ranged from 0.5 to 16 μg/ml, and most T. asahii isolates (76%, 34/45) were inhibited at safely achievable amphotericin B serum concentrations (≤ 2 μg/ml). However, 40% (18/45) of isolates were not killed at these concentrations (MFCs from 1.0 to 32 μg/ml). At concentrations ≥ 2 × MIC, amphotericin B exhibited fungicidal activity (< 99.9% reduction in CFU) over a 12‐hr time‐period; the maximal effect was achieved at ≥ 4 × MIC. Susceptibility testing confirmed the resistance of T. asahii to amphotericin B, and in vitro pharmacodynamic results also suggest that amphotericin B is not suitable therapy for T. asahii infection.

  DOI：

  10.1111/j.1348-0421.2002.tb02663.x

文献信息

• [EN] MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS<br/>[FR] COMPOSÉS DE MORPHOLINONE EN TANT QU'INHIBITEURS DE FACTEUR IXA
  申请人：MOCHIDA PHARM CO LTD

  公开号：WO2010065717A1

  公开（公告）日：2010-06-10

  The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

  本发明提供了如下描述的化合物I的化合物，或其药用可接受的盐或溶剂。本发明还提供包含一个或多个所述化合物的药物组合物，以及使用所述化合物治疗或预防血栓、栓塞、高凝血性或纤维变化的方法。
• PTERIDINONE COMPOUNDS AND USES THEREOF
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20190322673A1

  公开（公告）日：2019-10-24

  The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

  本发明提供了式I的化合物或其药学上可接受的盐，以及用于治疗细胞增殖性疾病（例如癌症）的药物组合物和使用方法。
• GLYCOSYLATED VALPROIC ACID ANALOGS AND USES THEREOF
  申请人：HEYMAN Norman S.

  公开号：US20130029924A1

  公开（公告）日：2013-01-31

  Glycosylated valproic acid and its analogs are provided. In some embodiments, the glycosylated valproic acid and its analogs have improved solubility and are ideal for drug delivery to treat a variety of diseases.

  提供了糖基化的丙戊酸及其类似物。在某些实施方式中，糖基化的丙戊酸及其类似物具有改善的溶解性，并且非常适合用于药物输送以治疗各种疾病。
• Nicotinamide Derivatives
  申请人：Blake Tanisha D.

  公开号：US20080146569A1

  公开（公告）日：2008-06-19

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds for the treatment of various diseases and conditions such as asthma.

  本发明涉及公式（I）的化合物及其药用可接受的盐和溶剂化合物，其中取代基如本文所定义，包含这种化合物的组合物以及这种化合物用于治疗各种疾病和状况，如哮喘。
• Phenylaminoethanol Derivates as Beta 2 Receptor Agonists
  申请人：Brown Daniel Alan

  公开号：US20070264262A1

  公开（公告）日：2007-11-15

  The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

  本发明涉及公式（1）的化合物以及制备、制备中间体、含有和使用这些衍生物的组合物的过程。根据本发明的化合物在许多疾病、紊乱和状况中非常有用，特别是在炎症、过敏和呼吸系统疾病、紊乱和状况中。